279 related articles for article (PubMed ID: 26656897)
1. Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products.
Kogan AE; Mukharyamova KS; Bereznikova AV; Filatov VL; Koshkina EV; Bloshchitsyna MN; Katrukha AG
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):542-50. PubMed ID: 26656897
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
[TBL] [Abstract][Full Text] [Related]
3. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products.
Madoiwa S; Kitajima I; Ohmori T; Sakata Y; Mimuro J
Thromb Res; 2013 Oct; 132(4):457-64. PubMed ID: 24011388
[TBL] [Abstract][Full Text] [Related]
4. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads.
Greenberg CS; Devine DV; McCrae KM
Am J Clin Pathol; 1987 Jan; 87(1):94-100. PubMed ID: 3541576
[TBL] [Abstract][Full Text] [Related]
5. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
[TBL] [Abstract][Full Text] [Related]
6. Validation, calibration, and specificity of quantitative D-dimer assays.
Dempfle CE
Semin Vasc Med; 2005 Nov; 5(4):315-20. PubMed ID: 16302152
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of antibody reactivity for FDP D-dimer fragments by Western blotting].
Wakabayashi S; Ishikawa S; Hirota-Kawadobora M; Fujihara N; Kamijyo Y; Yamauchi K; Terasawa F; Okumura N; Katsuyama T
Rinsho Byori; 2008 Jun; 56(6):449-54. PubMed ID: 18646629
[TBL] [Abstract][Full Text] [Related]
8. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of latex agglutination kits for detection of fibrin(ogen) degradation products and D-dimer in healthy horses and horses with severe colic.
Stokol T; Erb HN; De Wilde L; Tornquist SJ; Brooks M
Vet Clin Pathol; 2005 Dec; 34(4):375-82. PubMed ID: 16270263
[TBL] [Abstract][Full Text] [Related]
10. Basic Evaluation of the Newly Developed "Lias Auto P-FDP" Assay and the Influence of Plasmin-α2 Plasmin Inhibitor Complex Values on Discrepancy in the Comparison with "Lias Auto D-Dimer Neo" Assay.
Kumano O; Ieko M; Komiyama Y; Naito S; Yoshida M; Takahashi N; Ohmura K; Hayasaki J; Hayakawa M
Clin Lab; 2018 Apr; 64(4):433-442. PubMed ID: 29739066
[TBL] [Abstract][Full Text] [Related]
11. Role of D dimer in patients with elevated fibrinogen degradation products in serum: further study in chronic myelogenous leukemia.
Saito M; Asakura H; Jokaji H; Uotanzi C; Kumabashiri I; Yoshida T; Hashizume K; Matsuda T
Acta Haematol; 1990; 84(3):149-55. PubMed ID: 2123066
[TBL] [Abstract][Full Text] [Related]
12. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases.
Shibata T; Magari Y; Kamberi P; Ishii T; Tomo T; Yasumori R; Nasu M
Clin Nephrol; 1995 Aug; 44(2):91-5. PubMed ID: 8529315
[TBL] [Abstract][Full Text] [Related]
13. The Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group.
Dempfle CE; Zips S; Ergül H; Heene DL;
Thromb Haemost; 2001 Apr; 85(4):671-8. PubMed ID: 11341504
[TBL] [Abstract][Full Text] [Related]
14. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic possibilities of specific fibrin(ogen) degradation products in relation to venous thromboembolism.
Haas FJ; Schutgens RE; Biesma DH; Laterveer RH; Kluft C
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):297-304. PubMed ID: 23187785
[TBL] [Abstract][Full Text] [Related]
16. Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis.
Kumano O; Ieko M; Komiyama Y; Naito S; Yoshida M; Takahashi N; Ohmura K; Hayakawa M
Int J Lab Hematol; 2021 Aug; 43(4):813-820. PubMed ID: 33301236
[TBL] [Abstract][Full Text] [Related]
17. [Significance of urinary fibrin/fibrinogen degradation product (FDP) D-dimer measured by highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases].
Shibata T; Magari Y; Mizunaga S; Okabe E; Sumie A; Ishii T; Tomo T; Yasumori R; Nasu M
Nihon Jinzo Gakkai Shi; 1994 Jul; 36(7):805-12. PubMed ID: 8072218
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen/fibrin degradation products and D-dimer in clinical practice: interpretation of discrepant results.
Sato N; Takahashi H; Shibata A
Am J Hematol; 1995 Mar; 48(3):168-74. PubMed ID: 7864025
[TBL] [Abstract][Full Text] [Related]
19. [Persistent discrepancy between FDP and D-dimer in a patient with acute leukemia].
Sato N; Takahashi H; Nikuni K; Seki Y; Wada K; Tatewaki W; Shibata A
Rinsho Ketsueki; 1995 Mar; 36(3):212-7. PubMed ID: 7783324
[TBL] [Abstract][Full Text] [Related]
20. Unreliability of current serum fibrin degradation product (FDP) assays.
Gaffney PJ; Perry MJ
Thromb Haemost; 1985 Jun; 53(3):301-2. PubMed ID: 3901388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
